Liposomal delivery systems for intestinal lymphatic drug transport

被引：14

作者：

Ahn H. ^{[1
]}

Park J.-H. ^{[1
]}

机构：

[1] Department of Bio and Brain Engineering, Institute of Health Science and Technology, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon

来源：

Biomaterials Research | / 20卷 / 1期

关键词：

Chylomicron; First-pass metabolism; Intestinal lymphatic transport; Lipid; Liposome;

D O I：

10.1186/s40824-016-0083-1

中图分类号：

学科分类号：

摘要：

Intestinal lymphatic drug delivery has been widely studied because drugs can bypass the first-pass metabolism in the liver via the lymphatic route, which increases oral bioavailability. Various lipid-based nanoparticles have been used to deliver hydrophobic drugs to the lymphatic pathway. This review focuses on the liposomal delivery systems used for intestinal lymphatic drug transport. Liposomal formulations have attracted particular attention because they can stimulate the production of chylomicrons and the incorporated drugs readily associate with enterocytederived chylomicrons, enhancing lymphatic drug transport. We believe that a full understanding of their contribution to intestinal drug translocation will lead to effective oral delivery with liposomal formulations. © The Author(s). 2016.

引用

共 36 条

[1]

Goldberg M., Gomez-Orellana I., Challenges for the oral delivery of macromolecules, Nat Rev Drug Disc., 2, pp. 289-295, (2003)

[2]

Charman W.N.A., Stella V.J., Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules, Int J Pharm., 34, pp. 175-178, (1986)

[3]

Porter C.J.H., Trevaskis N.L., Charman W.N., Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs, Nat Rev Drug Disc., 6, pp. 231-248, (2007)

[4]

Ali Khan A., Mudassir J., Mohtar N., Darwis Y., Advanced drug delivery to the lymphatic system: lipid-based nanoformulations, Int J Nanomedicine., 8, pp. 2733-2744, (2013)

[5]

Wasan K.M., Et al., Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery, Nat Rev Drug Disc., 7, pp. 84-99, (2008)

[6]

Trevaskis N.L., Et al., From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity, Nat Rev Drug Disc., 14, pp. 781-803, (2015)

[7]

Shi Y., Burn P., Lipid metabolic enzymes: emerging drug targets for the treatment of obesity, Nat Rev Drug Disc., 3, pp. 695-710, (2004)

[8]

Porter C.J.H., Et al., Intestinal lymphatic drug transport: an update, Adv Drug Deliv Rev., 50, pp. 61-80, (2001)

[9]

Redgrave T.G., Chylomicron metabolism, Biochem Soc Trans., 32, pp. 79-82, (2004)

[10]

Khoo S-M., Et al., A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine, J Pharm Sci., 90, pp. 1599-1607, (2001)

← 1 2 3 4 →